Skip to main content
Psychedex

6Node page

what any key link opens

psx:substance/dmxe/section/chemistry.full@1

sectionreferenced by edges — no row of its own

derived from · upstream

feeds · downstream

none recorded

Closure of psx:substance/dmxe/section/chemistry.full@1: 30 upstream, 16 downstream.

psx:substance/dmxe/section/chemistry.full@1
├─ informed_by  claim/dae6346a-9b47-468c-a612-53d16ccaa5b3  Claim in chemistry — inconclusive  working
├─ informed_by  claim/8a57c61c-bdf9-4d05-b586-931d7c6beb11  Claim in chemistry — supported
  ├─ used  src/doi:10.1007/164_2018_148  1,2-Diarylethylamine- and Ketamine-Based New Psychoactive Substances
  ├─ used  src/doi:10.3390/separations12020044  Chiral Separation and Determination of Enantiomer Elution Order of Novel Ketamine Derivatives Using CE-UV and HPLC-UV-ORD
      ├─ used  src/doi:10.1007/7854_2022_313  Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic Psychedelics
      ├─ used  src/doi:10.1016/j.jphs.2022.09.005  Derivatives of methoxetamine and major methoxetamine metabolites potently block NMDA receptors
      ├─ used  src/doi:10.1248/yakushi.21-00235  Identification of Three Arylcyclohexylamines (MXPr, MXiPr, and DMXE) in Illegal Products
      ├─ used  src/doi:10.1093/jat/bku052  Analytical findings of an acute intoxication after inhalation of methoxetamine
      ├─ used  src/doi:10.1080/02791072.2019.1578444  Dorsolateral Prefrontal Cortex Impairment in Methoxetamine-Induced Psychosis: An 18F-FDG PET/CT Case Study
      ├─ used  src/doi:10.1002/nau.24341  What urologists need to know about ketamine-induced uropathy: A systematic review
      ├─ used  src/url:e8d823108bc2484d  Deoxymethoxetamine - Wikipedia
      ├─ used  src/url:3959d4322095326b  Deoxymethoxetamine (DMXE) New Drug Monograph — NPS Discovery
      ├─ used  src/url:6c05d211dca50db7  Deoxymethoxetamine - NCATS Inxight Drugs (FDA UNII: G32GTT7MGW)
      ├─ used  src/doi:10.1371/journal.pone.0059334  The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptor
      ├─ used  src/doi:10.1007/s00216-013-7051-6  Ketamine-derived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MSn
      ├─ used  src/url:35565ffe13e9cd03  Deoxymethoxetamine (DMXE) - PsychonautWiki Talk Page
      ├─ used  src/url:555df1cd5858173b  Deoxymethoxetamine — Chemical and pharmacological data compilation (Grokipedia)
      ├─ used  src/doi:10.1007/s00204-020-02693-7  Designer drugs: mechanism of action and adverse effects
      ├─ used  src/doi:10.1007/s00213-019-05219-x  The novel methoxetamine analogs N-ethylnorketamine, 2-MeO-N-ethylketamine, and 4-MeO-N-ethylketamine elicit rapid antidepressant effects via activation of AMPA and 5-HT2 receptors
      ├─ used  src/doi:10.1007/s13181-026-01122-y  Rhabdomyolysis and Acute Kidney Injury after Use of 3-Methyl-PCP: A Case Report
      ├─ used  src/doi:10.1093/jat/bky063  A Fatal Case Involving N-Ethyldeschloroketamine (2-Oxo-PCE) and Venlafaxine
      ├─ used  src/doi:10.1111/bju.16404  British Association of Urological Surgeons Consensus statements on the management of ketamine uropathy
      ├─ used  src/doi:10.3390/ph17040452  3-Methoxy-Phencyclidine Induced Psychotic Disorder: A Literature Review and an 18F-FDG PET/CT Case Report
      ├─ used  src/doi:10.1097/FBP.0000000000000241
      ├─ used  src/url:83d2032e67c03fc0  DMXE Experience Reports Index
      ├─ used  src/url:395779f3b4d2e972  Schedules of Controlled Substances: Placement of Methoxetamine (MXE) in Schedule I
      ├─ used  src/doi:10.1080/02791072.2017.1333660  Beyond Ketamine and Phencyclidine: Analytically Confirmed Use of Multiple Novel Arylcyclohexylamines
      ├─ derived_from  gen/2e90651a-683b-4474-8e30-70344735888e  Generation — pipeline-v5
      ├─ generated_by  pub/d8c42a17-fb0e-41d7-97b5-6f476ff00bf7  Publication — backfill
      └─ invalidated_by  pub/8a26a3ca-3af3-42ac-a207-96b82189aa68  Publication — publish
    ├─ used  version/1  Revision 1
    ├─ used  claim/39368d2a-546f-45a4-a188-a9b8a5c03ed4  Claim in summary — inconclusive  working
    ├─ used  claim/72a70653-03ed-4c24-a78f-2f99e9126d0d  Claim in history — inconclusive  working
    ├─ used  claim/a3e0ef59-fce5-41a2-a286-5cc2fc7f63d8  Claim in history — supported
    ├─ used  claim/e6f9dcd3-a5e4-4187-b1ab-f49c65497d3d  Claim in pharmacokinetic-detail — inconclusive  working
    ├─ used  claim/91d3b9dd-9a3e-4537-951a-023b3b519263  Claim in summary — inconclusive  working
    ├─ used  claim/7e3d5f8b-fe13-46b4-b09a-a1cfb8ffcf40  Claim in history — supported
    ├─ used  claim/43bc0b41-8bab-41e8-97c2-488bd25b3cc0  Claim in neuroscience — inconclusive  working
      ├─ derived_from  issue/notice@8d23c7a8206f  Issued notice
      ├─ derived_from  issue/info_card@198287cc03f6  Issued info_card
      ├─ derived_from  issue/emergency@ba304cf8bf8d  Issued emergency
      ├─ revised_from  version/2  r1.a1
      ├─ informed_by  section/summary.full@1
      ├─ informed_by  section/history.full@1
      ├─ informed_by  section/pharmacokinetic-detail.full@1
      └─ informed_by  section/neuroscience.full@1
… closure truncated at 200 nodes

indented by distance from this node, not by parentage

1Provenance card

the boundary, as counts

Sources

2518 with DOI

2 strong · 10 moderate · 13 weak

Compilations

22026-05-07T12:30:51.988Z

pipeline-v5 · prompt hash not recorded — run predates 2026-09

Decisions

48last ruled 2026-10-02

0 awaiting a ruling

Issued documents

42026-10-02T13:08:25.309Z

notice · info card · emergency

Searches

251 with no results

queries and counts on the build

Claims checked

6749 supported

49 supported · 18 not

Correspondence

0received

consent field ships in Phase 4

Edges

249

derivations recorded for this entity

Complete over 25 sources, 2 compilations, and 48 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/dmxe/archive

2Build

one panel per compilation run

generation run 2026-05-06

70 min completedmodel not recordedplan not recordedrun/42d38d55…

research

no artifact

draft

no artifact

audit

no artifact

verify

no artifact

simplify

no artifact

publish

no artifact

Selection

results seen0
selected by the model0
consumed as sources22

Verification

claims checked0
supported0
partially supported0
not supported0
inconclusive0
  • record
  • seen / partial
  • working

The model's own caveats

none raised on this run

Reproduce

inputs
22 source keys (listed under Sources)
plan
not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
model
not recorded
streams
none — agent transcripts are persisted from 2026-09 onward

generation run 2026-05-07

73 min completedmodel pipeline-v5plan not recordedrun/7e09431d…

research

citationsRegistryrecordresearchOutputworking

draft

articleDraftworking

audit

articleAuditedworking

verify

verificationResultworking

simplify

articleSimplifiedworking

publish

runMetarecordrunSummaryrecord

Selection

results seen115
selected by the model54
consumed as sources22

Verification

claims checked67
supported45
partially supported4
not supported2
inconclusive16
  • record
  • seen / partial
  • working

The model's own caveats

  • sparse_evidence
  • structural_inference
  • safety_data_unverified

Reproduce

inputs
22 source keys (listed under Sources)
plan
not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
model
pipeline-v5
streams
none — agent transcripts are persisted from 2026-09 onward
25 searches — query, source, results, what was kept and why
25 searches for this run
#sourcequeryseenkeptrationale
1PubChemDMXE / deoxymethoxetamine by name and CID 15701070511Primary chemical identity data verified
2PubMedmethoxetamine pharmacology NMDA receptor binding affinity ketamine dissociative32Key pharmacology data for structural analogs providing baseline for DMXE comparison
3PubMed3-methyl-2-oxo-PCE arylcyclohexylamine novel psychoactive substance83—
4WebSearchDMXE deoxymethoxetamine dissociative research chemical pharmacology effects 2020 2021 2022103Primary identification of substance-specific sources not available through academic APIs
5PubMedDerivatives methoxetamine NMDA receptors IC50 202211Key primary pharmacology paper measuring DMXE NMDA receptor activity directly
6WebSearchDMXE deoxymethoxetamine legal status UK Germany Australia102Legal status information not available via academic API tools
7GrokipediaDMXE pharmacology dose duration effects legal status13Secondary community-compiled source; useful for dose/duration data pending editorial review
8CFSREDMXE monograph11Authoritative forensic science reference with primary identification data
9PubMed · absenceDMXE deoxymethoxetamine dissociative0—Substance too new/niche for direct PubMed indexing under this name
10OpenAlexDMXE deoxymethoxetamine dissociative novel psychoactive11Directly mentions DMXE as one of the novel ketamine derivatives studied
11PubMedIdentification Three Arylcyclohexylamines MXPr MXiPr DMXE Illegal Products11First published paper specifically identifying DMXE in seized illegal products
12PubMedmethoxetamine intoxication case report hospital emergency22MXE adverse events applicable to DMXE by structural analogy
13PubMedketamine urological complications bladder cystitis recreational use95Class-level safety reference for dissociative drug bladder toxicity
14WebSearchDMXE deoxymethoxetamine harm reduction interactions warnings102No primary literature on DMXE interactions - harm reduction data from community sources only
15NCATS Inxight DrugsDMXE UNII G32GTT7MGW14Authoritative chemical identity verification from NIH database
16ErowidDMXE experience reports163User-report data on DMXE subjective effects and safety concerns
17WebSearchDMXE deoxymethoxetamine melting point solubility physical properties103Physical property data for chemical identity section
18MultipleCross-reference DMXE dose/duration data across sources32Triangulation of dose/duration data from multiple community sources for editorial dose proposal
19WebSearchDMXE deoxymethoxetamine Canada Australia New Zealand legal status103International legal status compilation; note Canada claim needs editorial verification as source is secondary
20Federal Register / DEAmethoxetamine MXE DEA Schedule I 2022 Federal Register12Critical for US legal status section of DMXE article
21WebSearchDMXE user reports dosage effects Bluelight 3D-MXE Warm-K82Community harm reduction data for dose/effect section
22NCATS Inxight DrugsDMXE UNII chemical identity verification11Authoritative government database confirmation of chemical identity
23PsychonautWiki Talk:DMXEDMXE dose duration classification12Most systematic community dose/duration data for DMXE
24PubMedmethoxetamine CYP metabolism pharmacokinetics N-deethylation hydroxylation glucuronidation11Direct metabolic data applicable to DMXE by structural analog
25Multiple primary/secondary sourcesDMXE legal status cross-reference54Legal status triangulation across multiple sources
67 claims by section — every cited sentence, checked against its source
safety21 · 17 ok

  • Seizures: Documented in acute MXE intoxication (inhalation route), presenting alongside sinus bradycardia (48 bpm), ST-segment elevation, and hyponatremia (127 mmol/L; MXE serum concentration 30 μg/L, urine 408 μg/L)partially supported

    Single MXE inhalation case: 21-year-old man found collapsed after suspected seizure. Sinus bradycardia, ST-segment elevation, hyponatremia. Serum 30 µg/L, urine 408 µg/L. bku052

  • Claim in safety — not_supportednot supportedworking →

  • Rhabdomyolysis: The first laboratory-confirmed case of 3-methyl-PCP use (a compound sharing DMXE's 3-methylphenyl ring substitution, differing in the nitrogen ring system and ketone) produced rhabdomyolysis and acute kidney injury. This structural parallel warrants caution but does not constitute direct evidence of rhabdomyolysis risk for DMXE.supported

    First laboratory-confirmed use of 3-methyl-PCP (a novel arylcyclohexylamine) causing rhabdomyolysis and acute kidney injury. s13181-026-01122-y

  • Fatal outcome: A fatal case involving O-PCE (N-ethyldeschloroketamine) — a compound sharing DMXE's ethylamino group and cyclohexanone core — occurred in combination with venlafaxine (femoral blood concentration 375 μg/L). No fatalities attributed to DMXE alone or in combination have been reported.partially supported

    Fatal case of 52-year-old man who abused N-ethyldeschloroketamine (2-Oxo-PCE/O-PCE) and venlafaxine. Tissue concentration data provided across multiple specimens. bky063

  • Urological damage: Chronic heavy ketamine use causes ketamine-induced uropathy (KIU), a progressive lower urinary tract syndrome characterized by inflammation, fibrosis, reduced bladder capacity, and in severe cases ureteral stenosis and renal failuresupported

    Systematic review of ketamine-induced uropathy (KIU): clinical presentation, pathophysiology, and treatments. Ketamine is a dissociative anesthetic; recreational abuse leads to urinary tract complications. nau.24341

  • Claim in safety — inconclusiveinconclusiveworking →

  • Neurological damage: Acute MXE intoxication (single intravenous dose) produced a substance-induced psychotic disorder with bilateral dorsolateral prefrontal cortex (DLPFC) metabolic deficit on ¹⁸F-FDG PET/CT, accompanied by severe dissociative symptoms, reduced motivation, and impaired verbal fluency and working memorysupported

    Case of 23-year-old man who developed substance-induced psychotic disorder after IV MXE injection. 18F-FDG PET/CT showed bilateral DLPFC metabolic deficit. Severe dissociative symptoms, reduced motivation, impaired verbal fluency and working memory. 02791072.2019.1578444

  • Persistent psychosis and cognitive impairment have also been documented following 3-MeO-PCP use, with PET/CT evidence of cerebral metabolic changessupported

    3-MeO-PCP-induced psychotic disorder in 29-year-old man. PET/CT case. Persistent psychotic symptoms and cognitive impairment documented. ph17040452

  • Claim in safety — inconclusiveinconclusiveworking →

  • Substance-induced psychotic disorder has been documented for both MXE and 3-MeO-PCP within the arylcyclohexylamine class, with cases persisting beyond the acute intoxication periodsupported

    Case of 23-year-old man who developed substance-induced psychotic disorder after IV MXE injection. 18F-FDG PET/CT showed bilateral DLPFC metabolic deficit. 02791072.2019.1578444

  • Substance-induced psychotic disorder has been documented for both MXE and 3-MeO-PCP within the arylcyclohexylamine class, with cases persisting beyond the acute intoxication periodsupported

    3-MeO-PCP-induced psychotic disorder in 29-year-old man. Persistent psychotic symptoms and cognitive impairment documented. ph17040452

  • Serotonergic agents (SSRIs, SNRIs, tramadol, MAO inhibitors): If DMXE retains SERT affinity analogous to MXE, co-administration with serotonergic drugs carries risk of serotonin syndromesupported

    Additional affinities for serotonin transporter and sigma receptors noted. journal.pone.0059334

  • The fatal case involving O-PCE (structurally related to DMXE) combined with the SNRI venlafaxine underscores this concernsupported

    Fatal case of 52-year-old man who abused N-ethyldeschloroketamine (2-Oxo-PCE/O-PCE) and venlafaxine. bky063

  • Psychotic disorders (personal or family history): NMDA antagonists are psychotomimetic agents; arylcyclohexylamine use has produced persistent psychosis in documented casessupported

    Case of 23-year-old man who developed substance-induced psychotic disorder after IV MXE injection. 02791072.2019.1578444

  • Psychotic disorders (personal or family history): NMDA antagonists are psychotomimetic agents; arylcyclohexylamine use has produced persistent psychosis in documented casessupported

    Persistent psychotic symptoms and cognitive impairment documented. ph17040452

  • Concurrent SNRI/SSRI use at high doses: Serotonin syndrome risk if DMXE possesses SERT activity; O-PCE + venlafaxine fatality is the most relevant casesupported

    Fatal case of 52-year-old man who abused N-ethyldeschloroketamine (2-Oxo-PCE/O-PCE) and venlafaxine. bky063

  • Claim in safety — not_supportednot supportedworking →

  • Renal impairment: Reduced clearance of compound and metabolites; rhabdomyolysis risk by structural parallel with 3-methyl-PCPsupported

    First laboratory-confirmed use of 3-methyl-PCP (a novel arylcyclohexylamine) causing rhabdomyolysis and acute kidney injury. s13181-026-01122-y

  • Hepatic impairment: Predicted CYP2B6/CYP3A4 metabolism; impaired hepatic function may alter drug levels unpredictablysupported

    Initial N-deethylation catalyzed by CYP2B6 and CYP3A4 in humans. s00216-013-7051-6

  • History of seizure disorder: Seizures documented in MXE intoxicationsupported

    21-year-old man found collapsed after suspected seizure. Seizure recurred during hospitalization. bku052

  • Lower urinary tract disease: Class-level risk of arylcyclohexylamine uropathy with repeated exposuresupported

    Systematic review of ketamine-induced uropathy (KIU): clinical presentation, pathophysiology, and treatments. Recreational abuse leads to urinary tract complications. nau.24341

summary9 · 4 ok

  • Claim in summary — inconclusiveinconclusiveworking →

  • The compound inhibits NMDA-mediated glutamatergic transmission with an IC₅₀ of 0.679 μM in mouse neuronal preparations, potency comparable to its parent compound methoxetamine (MXE; IC₅₀ = 0.524 μM)supported

    NMDA receptor IC50 values measured for methoxetamine derivatives including DMXE (IC50 0.679 µM), MXE (0.524 µM)... Patch-clamp recordings in NMDAR-expressing cartwheel interneurons of mice. j.jphs.2022.09.005

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Claim in summary — inconclusiveinconclusiveworking →

  • Class-level risks include seizures, cardiovascular disturbance (documented for MXE), substance-induced psychosis, and progressive lower urinary tract damage with chronic heavy use (established for ketamine)supported

    21-year-old man found collapsed after suspected seizure. Sinus bradycardia, ST-segment elevation, hyponatremia. Seizure recurred during hospitalization. bku052

  • Class-level risks include seizures, cardiovascular disturbance (documented for MXE), substance-induced psychosis, and progressive lower urinary tract damage with chronic heavy use (established for ketamine)supported

    Case of 23-year-old man who developed substance-induced psychotic disorder after IV MXE injection. 02791072.2019.1578444

  • Class-level risks include seizures, cardiovascular disturbance (documented for MXE), substance-induced psychosis, and progressive lower urinary tract damage with chronic heavy use (established for ketamine)supported

    Systematic review of ketamine-induced uropathy (KIU): clinical presentation, pathophysiology, and treatments. Ketamine is a dissociative anesthetic; recreational abuse leads to urinary tract complications. nau.24341

neuroscience7 · 4 ok

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • This AMPA receptor potentiation drives rapid synaptogenesis via downstream BDNF release and mTOR pathway activation — the mechanism underlying ketamine's rapid antidepressant effectssupported

    AMPAR activation and BDNF increases as downstream mechanisms. 7854_2022_313

  • MXE analogs have also demonstrated antidepressant-like behavioral effects via AMPA and 5-HT₂ receptor activation in animal modelssupported

    Three novel MXE analogs produce rapid antidepressant effects via AMPA and 5-HT2 receptor activation. s00213-019-05219-x

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Claim in neuroscience — inconclusiveinconclusiveworking →

  • Does DMXE inhibit the serotonin transporter (SERT)? If so, this would place DMXE closer to MXE (which possesses SERT affinity) than to ketamine in its pharmacological profile and would have significant implications for interaction risk with serotonergic drugs.supported

    Additional affinities for serotonin transporter and sigma receptors noted. journal.pone.0059334

  • What brain regions show altered metabolic activity during acute DMXE intoxication? MXE has been associated with bilateral dorsolateral prefrontal cortex metabolic deficit on PET/CT.supported

    18F-FDG PET/CT showed bilateral DLPFC metabolic deficit. 02791072.2019.1578444

pharmacology7 · 6 ok

  • Metabolic pathway predictions are derived from MXE metabolism data, which identified CYP2B6 and CYP3A4 as the primary enzymes catalyzing N-deethylation of MXE's ethylamino groupsupported

    Initial N-deethylation catalyzed by CYP2B6 and CYP3A4 in humans. s00216-013-7051-6

  • Irie et al. (2022) provided the only published direct measurement of DMXE activity at NMDA receptors, reporting an IC₅₀ of 0.679 μM via whole-cell patch-clamp recordings in NMDAR-expressing cartwheel interneurons of the mouse dorsal cochlear nucleus. In silico molecular docking confirmed that DMXE binds at the PCP site within the NMDA channelsupported

    NMDA receptor IC50 values measured for methoxetamine derivatives including DMXE (IC50 0.679 µM)... Patch-clamp recordings in NMDAR-expressing cartwheel interneurons of mice. In silico docking studies confirm binding interactions. j.jphs.2022.09.005

  • Irie et al. (2022) provided the only published direct measurement of DMXE activity at NMDA receptors, reporting an IC₅₀ of 0.679 μM via whole-cell patch-clamp recordings in NMDAR-expressing cartwheel interneurons of the mouse dorsal cochlear nucleus. In silico molecular docking confirmed that DMXE binds at the PCP site within the NMDA channelsupported

    NMDA receptor IC50 values measured for methoxetamine derivatives including DMXE (IC50 0.679 µM)... In silico docking studies confirm binding interactions. j.jphs.2022.09.005

  • This potency is comparable to MXE (IC₅₀ = 0.524 μM) and methoxisopropamine (IC₅₀ = 0.661 μM), and substantially greater than the MXE metabolite N-desethyl MXE (IC₅₀ = 1.649 μM), as measured in the same assay system.supported

    NMDA receptor IC50 values measured for methoxetamine derivatives including DMXE (IC50 0.679 µM), MXE (0.524 µM), methoxisopropamine (0.661 µM), N-desethyl MXE (1.649 µM)... j.jphs.2022.09.005

  • By structural analogy with MXE, which was profiled across 46 CNS receptor targets, DMXE may possess affinity for the serotonin transporter (SERT) — a property that contributes to MXE's reported empathogenic qualitypartially supported

    MXE and 3-MeO-PCE confirmed as high affinity NMDA receptor (PCP-site) ligands. Additional affinities for serotonin transporter and sigma receptors noted. journal.pone.0059334

  • Claim in pharmacology — inconclusiveinconclusiveworking →

  • Secondary pathways likely include cyclohexyl and aryl ring hydroxylation, with Phase II conjugation (glucuronidation, sulfation) of hydroxylated metabolitessupported

    MXE metabolism characterized: N-deethylation, O-demethylation, hydroxylation, glucuronidation/sulfation. s00216-013-7051-6

pharmacokinetic-detail6 · 4 ok

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • MXE metabolism proceeds primarily via N-deethylation (CYP2B6, CYP3A4), O-demethylation (CYP2B6, CYP2C19), and ring hydroxylation, with subsequent Phase II glucuronidation and sulfationsupported

    MXE metabolism characterized: N-deethylation, O-demethylation, hydroxylation, glucuronidation/sulfation. Initial N-deethylation catalyzed by CYP2B6 and CYP3A4 in humans. s00216-013-7051-6

  • The predicted primary metabolic route is therefore N-deethylation to nor-DMXE (N-desethyl-DMXE), catalyzed by CYP2B6 and CYP3A4supported

    Initial N-deethylation catalyzed by CYP2B6 and CYP3A4 in humans. s00216-013-7051-6

  • For MXE, the analogous metabolite N-desethyl MXE showed reduced NMDA antagonist potency (IC₅₀ = 1.649 μM vs. 0.524 μM for MXE), suggesting that N-deethylation may represent a deactivation pathway — but direct measurement for DMXE metabolites is lacking.supported

    MXE (0.524 µM)... N-desethyl MXE (1.649 µM). j.jphs.2022.09.005

  • Claim in pharmacokinetic-detail — inconclusiveinconclusiveworking →

  • DMXE is not detected by standard immunoassay drug screening panels; definitive identification requires liquid chromatography–tandem mass spectrometry (LC-MS/MS) or gas chromatography–mass spectrometry (GC-MS).supported

    Notes novel designer drugs may remain undetected by routine screening. s00204-020-02693-7

history5 · 4 ok

  • Claim in history — inconclusiveinconclusiveworking →

  • This pattern — novel arylcyclohexylamine analogs appearing in response to the scheduling of predecessors — is well-established within the classsupported

    Historical context of PCP analogs on illicit markets since 1960s. Covers methoxetamine, deschloroketamine, and 2-fluoro-2-deschloroketamine. 164_2018_148

  • Tanaka et al. (2022) published the first peer-reviewed forensic characterization, identifying DMXE alongside MXPr and MXiPr in seized products in Japan using NMR spectroscopy and mass spectrometrysupported

    DMXE, MXPr, and MXiPr identified in illegal products seized in Japan. Analytical data including NMR and mass spectrometry provided for forensic identification. yakushi.21-00235

  • The first primary pharmacological data on DMXE appeared in Irie et al. (2022), published in the Journal of Pharmacological Sciences, which measured NMDA receptor IC₅₀ values for DMXE and several MXE metabolites in mouse neuronal preparationssupported

    NMDA receptor IC50 values measured for methoxetamine derivatives including DMXE (IC50 0.679 µM), MXE (0.524 µM)... Patch-clamp recordings in NMDAR-expressing cartwheel interneurons of mice. j.jphs.2022.09.005

  • Seibert et al. (2025) subsequently conducted the first enantioseparation of DMXE among 11 novel ketamine derivatives, using capillary electrophoresis and HPLC with chiral stationary phasessupported

    Chiral separation methods developed for 11 novel ketamine derivatives including DMXE. CE and HPLC methods tested. Some compounds enantioseparated for first time due to novelty. separations12020044

comparative-pharmacology4 · 3 ok

  • Claim in comparative-pharmacology — inconclusiveinconclusiveworking →

  • DMXE and MXE are approximately equipotent at the NMDA receptor (IC₅₀ ratio ≈ 1.3:1), indicating that the 3-methoxy to 3-methyl substitution has minimal impact on primary target affinitysupported

    DMXE (IC50 0.679 µM), MXE (0.524 µM). j.jphs.2022.09.005

  • N-deethylation substantially reduces potency (approximately 3-fold for MXE → N-desethyl MXE), while the O-desmethyl metabolite of MXE is the most potent compound in the series.supported

    MXE (0.524 µM)... N-desethyl MXE (1.649 µM), O-desmethyl MXE (0.227 µM). j.jphs.2022.09.005

  • MXE has been profiled across 46 CNS receptors, revealing appreciable SERT affinity alongside NMDA antagonismpartially supported

    Pharmacological profiles of novel ketamine and PCP analogues via NIMH PDSP. MXE and 3-MeO-PCE confirmed as high affinity NMDA receptor (PCP-site) ligands. Additional affinities for serotonin transporter and sigma receptors noted. journal.pone.0059334

receptor-pharmacology3 · 3 ok

  • The only published receptor-level data for DMXE derives from Irie et al. (2022), who measured functional NMDA receptor inhibition using whole-cell patch-clamp electrophysiology in mouse dorsal cochlear nucleus cartwheel interneurons.supported

    Patch-clamp recordings in NMDAR-expressing cartwheel interneurons of mice. j.jphs.2022.09.005

  • DMXE's IC₅₀ of 0.679 μM places it within the same potency range as its parent compound MXE (IC₅₀ = 0.524 μM), indicating that replacement of the 3-methoxy group with a methyl group does not substantially diminish NMDA antagonist potencysupported

    NMDA receptor IC50 values measured for methoxetamine derivatives including DMXE (IC50 0.679 µM), MXE (0.524 µM). j.jphs.2022.09.005

  • By structural analogy with MXE, which demonstrated appreciable SERT affinity alongside NMDA antagonism, DMXE may possess secondary serotonergic activitysupported

    MXE and 3-MeO-PCE confirmed as high affinity NMDA receptor (PCP-site) ligands. Additional affinities for serotonin transporter and sigma receptors noted. journal.pone.0059334

chemistry2 · 1 ok

  • Claim in chemistry — inconclusiveinconclusiveworking →

  • Seibert et al. (2025) achieved the first enantioseparation of DMXE using capillary electrophoresis (CE-UV) and HPLC with chiral stationary phases (HPLC-UV-ORD), establishing elution order and providing methods for forensic differentiation of enantiomerssupported

    CE and HPLC methods tested. Enantiomer elution order determined using optical rotation detector. Some compounds enantioseparated for first time due to novelty. separations12020044

clinical-evidence2 · 2 ok

  • By analogy with ketamine, NMDA receptor antagonism has been associated with rapid-onset antidepressant effects, mediated through downstream AMPA receptor potentiation and BDNF-dependent synaptogenesissupported

    Historical and mechanistic review of ketamine as antidepressant. AMPAR activation and BDNF increases as downstream mechanisms. 7854_2022_313

  • Structurally related MXE analogs (N-ethylnorketamine, 2-MeO-NEK, 4-MeO-NEK) have demonstrated antidepressant-like activity in rodent models via AMPA and 5-HT₂ receptor activationsupported

    Three novel MXE analogs produce rapid antidepressant effects via AMPA and 5-HT2 receptor activation. NMDA receptor antagonism as initial mechanism. s00213-019-05219-x

legal-status1 · 1 ok

  • DMXE satisfies both structural similarity (differs from Schedule I MXE by a single functional group substitution) and pharmacological similarity (comparable NMDA antagonist potency, IC₅₀ ratio ≈ 1.3:1)supported

    NMDA receptor IC50 values measured for methoxetamine derivatives including DMXE (IC50 0.679 µM), MXE (0.524 µM). j.jphs.2022.09.005

3Sources

22 consumed · sorted by year · feeds = sections resting on it

Sources
yearsourcetierstatusfeeds
2026Rhabdomyolysis and Acute Kidney Injury after Use of 3-Methyl-PCP: A Case ReportDeutsch AB, Ebeling-Koning NE, Krotulski AJ, Walton SE, Katz KD · Journal of Medical Toxicologydoi:10.1007/s13181-026-01122-yweakconsumed1 section
2025Chiral Separation and Determination of Enantiomer Elution Order of Novel Ketamine Derivatives Using CE-UV and HPLC-UV-ORDSeibert E, Hubner EM, Schmid MG · Separationsdoi:10.3390/separations12020044moderateconsumed4 sections
20243-Methoxy-Phencyclidine Induced Psychotic Disorder: A Literature Review and an 18F-FDG PET/CT Case ReportPepe M, Di Nicola M, Cocciolillo F, Chiappini S, Martinotti G, Calcagni ML, Sani G · Pharmaceuticals (Basel)doi:10.3390/ph17040452weakconsumed1 section
2024British Association of Urological Surgeons Consensus statements on the management of ketamine uropathyBelal M, Downey A, Doherty R, Ali A, Hashim H, Kozan A, Kujawa M, Pakzad M, Rashid T, Osman N, Sahai A, Biers S · BJU Internationaldoi:10.1111/bju.16404moderateconsumed1 section
2024Deoxymethoxetamine - NCATS Inxight Drugs (FDA UNII: G32GTT7MGW)url:6c05d211dca50db7weakconsumedcited only
2024Deoxymethoxetamine - Wikipediaurl:e8d823108bc2484dweakconsumedcited only
2024Deoxymethoxetamine (DMXE) - PsychonautWiki Talk Pageurl:35565ffe13e9cd03weakconsumedcited only
2024DMXE Experience Reports IndexErowidurl:83d2032e67c03fc0weakconsumedcited only
2022Derivatives of methoxetamine and major methoxetamine metabolites potently block NMDA receptorsIrie T, Yanase Y, Demizu Y, Usami M, Kikura-Hanajiri R · Journal of Pharmacological Sciencesdoi:10.1016/j.jphs.2022.09.005moderateconsumed7 sections
2022Identification of Three Arylcyclohexylamines (MXPr, MXiPr, and DMXE) in Illegal ProductsTanaka R, Kawamura M, Mizutani S, Hakamatsuka T, Kikura-Hanajiri R · Yakugaku Zasshi (Journal of the Pharmaceutical Society of Japan)doi:10.1248/yakushi.21-00235moderateconsumed3 sections
2022Ketamine for Depression: Advances in Clinical Treatment, Rapid Antidepressant Mechanisms of Action, and a Contrast with Serotonergic PsychedelicsKojic M, Saelens J, Kadriu B, Zarate CA, Kraus C · Current Topics in Behavioral Neurosciencesdoi:10.1007/7854_2022_313moderateconsumed2 sections
2020Designer drugs: mechanism of action and adverse effectsLuethi D, Liechti ME · Archives of Toxicologydoi:10.1007/s00204-020-02693-7strongconsumed1 section
2020What urologists need to know about ketamine-induced uropathy: A systematic reviewCastellani D, Pirola GM, Gubbiotti M, Rubilotta E, Gudaru K, Gregori A, Dellabella M · Neurourology and Urodynamicsdoi:10.1002/nau.24341strongconsumed2 sections
2019A Fatal Case Involving N-Ethyldeschloroketamine (2-Oxo-PCE) and VenlafaxineTheofel N, Möller P, Vejmelka E, Kastner K, Roscher S, Scholtis S, Tsokos M · Journal of Analytical Toxicologydoi:10.1093/jat/bky063weakconsumed1 section
2019Dorsolateral Prefrontal Cortex Impairment in Methoxetamine-Induced Psychosis: An 18F-FDG PET/CT Case StudyMoccia L, Tofani A, Mazza M, Covino M, Martinotti G, Schifano F, Janiri L, Di Nicola M · Journal of Psychoactive Drugsdoi:10.1080/02791072.2019.1578444weakconsumed3 sections
2019The novel methoxetamine analogs N-ethylnorketamine, 2-MeO-N-ethylketamine, and 4-MeO-N-ethylketamine elicit rapid antidepressant effects via activation of AMPA and 5-HT2 receptorsSayson LV, Botanas CJ, Custodio RJP, Abiero A, Kim M, Lee HJ, Kim HJ, Yoo SY, Lee KW, Ryu HW, Acharya S, Kim KM, Lee YS, Cheong JH · Psychopharmacologydoi:10.1007/s00213-019-05219-xmoderateconsumed2 sections
20181,2-Diarylethylamine- and Ketamine-Based New Psychoactive SubstancesWallach J, Brandt SD · Handbook of Experimental Pharmacologydoi:10.1007/164_2018_148moderateconsumed4 sections
2017Beyond Ketamine and Phencyclidine: Analytically Confirmed Use of Multiple Novel ArylcyclohexylaminesThornton S, Lisbon D, Lin T, Gerona R · Journal of Psychoactive Drugsdoi:10.1080/02791072.2017.1333660weakconsumedcited only
2016Methoxetamine, a novel psychoactive substance with serious adverse pharmacological effects: a review of case reports and preclinical findingsZanda MT, Fadda P, Chiamulera C, Fratta W, Fattore L · Behavioural Pharmacologydoi:10.1097/fbp.0000000000000241moderateconsumedcited only
2014Analytical findings of an acute intoxication after inhalation of methoxetamineImbert L, Boucher A, Delhome G, Cueto T, Boudinaud M, Maublanc J, Dulaurent S, Descotes J, Lachatre G, Gaulier JM · Journal of Analytical Toxicologydoi:10.1093/jat/bku052weakconsumed2 sections
2013Ketamine-derived designer drug methoxetamine: metabolism including isoenzyme kinetics and toxicological detectability using GC-MS and LC-(HR-)MSnMeyer MR, Bach M, Welter J, Bovens M, Turcant A, Maurer HH · Analytical and Bioanalytical Chemistrydoi:10.1007/s00216-013-7051-6moderateconsumed3 sections
2013The ketamine analogue methoxetamine and 3- and 4-methoxy analogues of phencyclidine are high affinity and selective ligands for the glutamate NMDA receptorRoth BL, Gibbons S, Arunotayanun W, Huang XP, Setola V, Treble R, Iversen L · PLoS ONEdoi:10.1371/journal.pone.0059334moderateconsumed5 sections
—Deoxymethoxetamine — Chemical and pharmacological data compilation (Grokipedia)url:555df1cd5858173b—unknowncited only
—Deoxymethoxetamine (DMXE) New Drug Monograph — NPS Discoveryurl:3959d4322095326b—unknowncited only
—Schedules of Controlled Substances: Placement of Methoxetamine (MXE) in Schedule Iurl:395779f3b4d2e972—unknowncited only
—Searched PubMed for "DMXE deoxymethoxetamine dissociative" — no resultsabsenceno results—

4Docket

one filing per activity — decisions, correspondence, reports

  1. 0012026-05-07revisionRevision 1

    Initial LLM generation (v5 pipeline, wiki, prose phase)

    psx:substance/dmxe/version/1
  2. 0022026-06-04proposal42 value proposals approved together

    one review action inferred from a shared reviewer and instant — the graph records one activity per proposal

    42 items in this filing

    • contraindication · other
    • contraindication · other
    • contraindication · cardiovascular
    • contraindication · renal
    • contraindication · hepatic
    • contraindication · neurological
    • contraindication · pregnancy_breastfeeding
    • contraindication · other
    • dose_tier · threshold
    • dose_tier · light
    • dose_tier · common
    • dose_tier · strong
    • dose_tier · heavy
    • timeline · insufflated · onset
    • timeline · insufflated · come_up
    • timeline · insufflated · peak
    • timeline · insufflated · resolution
    • timeline · insufflated · afterglow
    • timeline · oral · onset
    • timeline · oral · come_up
    • timeline · oral · peak
    • timeline · oral · resolution
    • timeline · oral · afterglow
    • toxicity
    • dependence · full
    • withdrawal
    • tolerance
    • dosage · insufflated
    • dosage · oral
    • duration · insufflated · onset
    • duration · insufflated · come_up
    • duration · insufflated · peak
    • duration · insufflated · offset
    • duration · insufflated · total
    • duration · insufflated · aftereffects
    • duration · oral · onset
    • duration · oral · come_up
    • duration · oral · peak
    • duration · oral · offset
    • duration · oral · total
    • duration · oral · aftereffects
    psx:substance/dmxe/proposal/contraindication/83bb4765-4249-47a5-90cb-6907a1e6f02b
  3. 0032026-06-04publicationPublication — backfill
    psx:substance/dmxe/pub/d8c42a17-fb0e-41d7-97b5-6f476ff00bf7
  4. 0042026-10-02rulingRuling — psx:substance/dmxe/proposal/article_section_proposals/a064de82-8d8d-45a6-a0ea-161a306439fcfounder
    psx:substance/dmxe/ruling/harm-reduction-headings/a064de82-8d8d-45a6-a0ea-161a306439fc
  5. 0052026-10-02rulingRuling — psx:substance/dmxe/proposal/article_section_proposals/cf67f045-5a09-4aab-8051-5034587cbce5founder
    psx:substance/dmxe/ruling/harm-reduction-headings/cf67f045-5a09-4aab-8051-5034587cbce5
  6. 0062026-10-02revisionr1.a1

    no edit summary recorded

    psx:substance/dmxe/version/2
  7. 0072026-10-02publicationPublication — publishagent-psx
    psx:substance/dmxe/pub/8a26a3ca-3af3-42ac-a207-96b82189aa68

5Issued documents

what the notice, info card and emergency page said, by hash

Issued documents
documentcontent hashissuedfrom versionsuperseded
info_card699fada047df70a07038ef7d…2026-10-02 13:08Revision 2current
emergencyba304cf8bf8de5b4ec66cb2b…2026-09-04 04:29Revision 1current
info_card198287cc03f60080b2fe5a9c…2026-09-04 04:29Revision 1superseded2026-10-02
notice8d23c7a8206ff8cbbfe1dc1c…2026-09-04 04:29Revision 1current